Nurix Therapeutics NRIX Stock
Nurix Therapeutics Price Chart
Nurix Therapeutics NRIX Financial and Trading Overview
| Nurix Therapeutics stock price | 23.83 USD |
| Previous Close | 23.06 USD |
| Open | 22.56 USD |
| Bid | 16.14 USD x 200 |
| Ask | 27.3 USD x 200 |
| Day's Range | 21.23 - 22.75 USD |
| 52 Week Range | 8.2 - 25.09 USD |
| Volume | 1.54M USD |
| Avg. Volume | 1.98M USD |
| Market Cap | 2.36B USD |
| Beta (5Y Monthly) | 1.802 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.5 USD |
NRIX Valuation Measures
| Enterprise Value | 1.97B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.417861 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 64.104935 |
| Price/Book (mrq) | 4.8828206 |
| Enterprise Value/Revenue | 53.623 |
| Enterprise Value/EBITDA | -5.582 |
Trading Information
Nurix Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.802 |
| 52-Week Change | 81.71% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 25.09 USD |
| 52 Week Low | 8.2 USD |
| 50-Day Moving Average | 18.26 USD |
| 200-Day Moving Average | 16.04 USD |
NRIX Share Statistics
| Avg. Volume (3 month) | 1.98M USD |
| Avg. Daily Volume (10-Days) | 2.03M USD |
| Shares Outstanding | 103.78M |
| Float | 82.79M |
| Short Ratio | 4.72 |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 114.25% |
| Shares Short | 17.8M |
| Short % of Float | 17.33% |
| Short % of Shares Outstanding | 17.15% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | November 30, 2025 |
| Most Recent Quarter (mrq) | May 31, 2026 |
| Next Fiscal Year End | November 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1041.73% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.056% |
| Return on Equity (ttm) | -80.29% |
Income Statement
| Revenue (ttm) | 36.77M USD |
| Revenue Per Share (ttm) | 0.37 USD |
| Quarterly Revenue Growth (yoy) | -79.50% |
| Gross Profit (ttm) | -304167008 USD |
| EBITDA | -353180000 USD |
| Net Income Avi to Common (ttm) | -341351008 USD |
| Diluted EPS (ttm) | -3.46 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 443.53M USD |
| Total Cash Per Share (mrq) | 4.27 USD |
| Total Debt (mrq) | 58.14M USD |
| Total Debt/Equity (mrq) | 14.44 USD |
| Current Ratio (mrq) | 6.338 |
| Book Value Per Share (mrq) | 4.651 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -293704000 USD |
| Levered Free Cash Flow (ttm) | -164635872 USD |
Profile of Nurix Therapeutics
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 1600 Sierra Point Parkway |
| ZIP | 94005 |
| Phone | 415 660 5320 |
| Website | https://www.nurixtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 317 |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Q&A For Nurix Therapeutics Stock
What is a current NRIX stock price?
Nurix Therapeutics NRIX stock price today per share is 23.83 USD.
How to purchase Nurix Therapeutics stock?
You can buy NRIX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nurix Therapeutics?
The stock symbol or ticker of Nurix Therapeutics is NRIX.
Which industry does the Nurix Therapeutics company belong to?
The Nurix Therapeutics industry is Biotechnology.
How many shares does Nurix Therapeutics have in circulation?
The max supply of Nurix Therapeutics shares is 103.78M.
What is Nurix Therapeutics Price to Earnings Ratio (PE Ratio)?
Nurix Therapeutics PE Ratio is now.
What was Nurix Therapeutics earnings per share over the trailing 12 months (TTM)?
Nurix Therapeutics EPS is -3.46 USD over the trailing 12 months.
Which sector does the Nurix Therapeutics company belong to?
The Nurix Therapeutics sector is Healthcare.
Nurix Therapeutics NRIX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26232.37 USD — |
+0.48
|
5.22B USD — | 26041.13 USD — | 26316.81 USD — | — - | 5.22B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2296.8 USD — |
-0.16
|
— — | 2271.37 USD — | 2311.92 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6554.84 USD — |
+0.59
|
— — | 6454.97 USD — | 6560.7 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1250.71 USD — |
+0.76
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}